🎯 Drug Targets

Small molecule inhibitor of complement activation or convertase activity

Small molecule inhibitor of anti-apoptotic protein function

RAB7A inhibitors or modulators would block or enhance GTPase-mediated late endosome and lysosome trafficking, disrupting autophagy flux and lysosomal degradation pathways. This can either impair pathogenic protein clearance (in certain cancers) or restore lysosomal function (in storage disorders and neurodegeneration).

G3BP1 inhibitors would prevent stress granule assembly and stabilization by disrupting the interaction between G3BP1 and its binding partners, potentially reducing pathological aggregation of TDP-43 and FUS proteins. This mechanism could alleviate neurodegeneration in conditions characterized by aberrant stress granule formation and RNA metabolism dysfunction.

Monoclonal antibodies or soluble receptors that neutralize TNF-alpha activity

Small molecule inhibitors targeting NLRP3 inflammasome assembly or activation

MIRO1-targeting drugs modulate GTPase activity to enhance mitochondrial transport along axons and improve mitochondrial quality control through selective autophagy. By regulating MIRO1's interaction with kinesin motor proteins and PINK1-mediated mitophagy, these compounds restore energy homeostasis and reduce neuronal stress in neurodegenerative diseases.

Complement cascade inhibitor or antibody-mediated neutralization

Small molecule agonists or antagonists of cGAS-STING pathway activation

RAB27A inhibitors would block GTP binding or GTPase activity, preventing the recruitment of effector proteins required for vesicular trafficking and exosome biogenesis. This would reduce the release of extracellular vesicles and potentially modulate intercellular communication in disease states involving excessive exosome-mediated signaling or pathological cargo transfer.

Complement cascade inhibitor or antibody-mediated neutralization

Calcium-dependent phospholipid binding protein modulator

Prioritized from 1 SciDEX hypotheses, including: Mechanosensitive Ion Channel Reprogramming

Small molecule or antisense-based inhibitors would disrupt SYNCRIP's RNA-binding capability, reducing its ability to facilitate mRNA transport and local protein synthesis, potentially modulating disease pathways in neurological disorders or cancers where SYNCRIP dysfunction is implicated.

PYCARD acts as a critical adaptor protein in inflammasome activation, facilitating pro-inflammatory caspase-1 recruitment and subsequent IL-1β/IL-18 processing, which contributes to neuroinflammatory processes in neurodegenerative conditions like Alzheimer's and Parkinson's disease. Its protein-protein interaction domains mediate inflammatory signal transduction, potentially amplifying neuronal damage through excessive immune response activation.

Prioritized from 1 SciDEX hypotheses, including: Context-Dependent CRISPR Activation in Specific Neuronal Subtypes

Drugs targeting RELN would primarily work by enhancing reelin expression or signaling through its receptors (VLDLR and ApoER2) to promote neuronal migration, synaptic plasticity, and cognitive function. Alternatively, pathway modulators could enhance downstream signaling cascades (Dab1-mediated pathways) to compensate for reelin deficiency or dysfunction.

Prioritized from 1 SciDEX hypotheses, including: Lipid Droplet Dynamics as Phenotype Switches

Prioritized from 1 SciDEX hypotheses, including: Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits

Prioritized from 1 SciDEX hypotheses, including: Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery

Prioritized from 1 SciDEX hypotheses, including: Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring

Prioritized from 1 SciDEX hypotheses, including: Synthetic Biology Approach: Designer Mitochondrial Export Systems

Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR

Prioritized from 1 SciDEX hypotheses, including: Programmable Neuronal Circuit Repair via Epigenetic CRISPR

No known druggable mechanism